Cargando…

Activity of 8F4, a T cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo

The PR1 peptide, derived from the leukemia-associated antigens proteinase 3 and neutrophil elastase, is overexpressed on HLA-A2 in acute myeloid leukemia (AML). We developed a high affinity T cell receptor-like murine monoclonal antibody, 8F4, which binds to the PR1/HLA-A2 complex, mediates lysis of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sergeeva, Anna, He, Hong, Ruisaard, Kathryn, St. John, Lisa, Alatrash, Gheath, Clise-Dwyer, Karen, Li, Dan, Patenia, Rebecca, Hong, Richard, Sukhumalchandra, Pariya, You, M. James, Gagea, Mihai, Ma, Qing, Molldrem, Jeffrey J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935597/ https://www.ncbi.nlm.nih.gov/pubmed/27055866 http://dx.doi.org/10.1038/leu.2016.57

Ejemplares similares

A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2
por: Herrmann, Amanda C., et al.
Publicado: (2019)

PR1-Specific T Cells Are Associated with Unmaintained Cytogenetic Remission of Chronic Myelogenous Leukemia After Interferon Withdrawal
por: Kanodia, Shreya, et al.
Publicado: (2010)

Targeting PR1 in myeloid leukemia
por: Alatrash, Gheath, et al.
Publicado: (2017)

PR1 Peptide Vaccine Induces Specific Immunity With Clinical Responses In Myeloid Malignancies
por: Qazilbash, Muzaffar H., et al.
Publicado: (2016)

Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target
por: Khan, Maliha, et al.
Publicado: (2018)

Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target
por: Alatrash, Gheath, et al.
Publicado: (2016)

Fucosylation enhances activity of cytotoxic T lymphocytes against breast cancer
por: Qiao, Na, et al.
Publicado: (2015)

Targeting cathepsin G in myeloid leukemia
por: Alatrash, Gheath
Publicado: (2013)

Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8(+) Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
por: Chacon, Jessica Ann, et al.
Publicado: (2013)

Common Minor Histocompatibility Antigen Discovery Based upon Patient Clinical Outcomes and Genomic Data
por: Armistead, Paul M., et al.
Publicado: (2011)

Immune checkpoints: A therapeutic target in triple negative breast cancer
por: Chawla, Akhil, et al.
Publicado: (2014)

Adoptive T-cell therapy for Leukemia
por: Garber, Haven R, et al.
Publicado: (2014)

Delta-24-RGD Oncolytic Adenovirus Elicits Anti-Glioma Immunity in an Immunocompetent Mouse Model
por: Jiang, Hong, et al.
Publicado: (2014)

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2022)

CD9 Is a Very Helpful Marker for Discriminating AML-M3 from HLA-DR-Negative Non-M3 AML
por: Satlsar, Esmaeil Shahabi, et al.
Publicado: (2020)

Display technologies: Application for the discovery of drug and gene delivery agents()
por: Sergeeva, Anna, et al.
Publicado: (2006)

Loss of Mismatched HLA Detected in the Peripheral Blood of an AML Patient who Relapsed After Haploidentical Hematopoietic Stem Cell Transplantation
por: Park, Borae G., et al.
Publicado: (2015)

Isolation, culture, and immunophenotypic analysis of bone marrow HSPCs from patients with myelodysplastic syndromes
por: Ganan-Gomez, Irene, et al.
Publicado: (2022)

995. Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline
por: Campbell, Thomas, et al.
Publicado: (2020)

Comment: In Response to “CD9 Is a Very Helpful Marker for Discriminating AML-M3 from HLA-DR-Negative Non-M3 AML”
por: Gajendra, Smeeta
Publicado: (2020)

HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation
por: Roerden, Malte, et al.
Publicado: (2020)

Divergent CD4(+) T-cell profiles are associated with anti-HLA alloimmunization status in platelet-transfused AML patients
por: Khelfa, Mehdi, et al.
Publicado: (2023)

P1254: BASELINE HLA-DR-RESTRICTED NEOANTIGEN BURDEN OF AML BLASTS IMPACTS ON HLA-DR GENE EXPRESSION AT RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANT
por: Charrot, Sarah, et al.
Publicado: (2023)

Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML
por: Herbrich, Shelley, et al.
Publicado: (2021)

IRF8 Is an AML-Specific Susceptibility Factor That Regulates Signaling Pathways and Proliferation of AML Cells
por: Liss, Franziska, et al.
Publicado: (2021)

Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor
por: Nemeckova, Sarka, et al.
Publicado: (2022)

An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML
por: van der Lee, Dyantha I., et al.
Publicado: (2021)

The smallest 4f-metalla-aromatic molecule of cyclo-PrB(2)(−) with Pr–B multiple bonds
por: Wang, Zhen-Ling, et al.
Publicado: (2022)

Navigating the Intersection of PrEP and Medicaid
por: Seiler, Naomi, et al.
Publicado: (2022)

NHERF1/EBP50 Suppresses Wnt-β-Catenin Pathway–Driven Intestinal Neoplasia()
por: Georgescu, Maria-Magdalena, et al.
Publicado: (2016)

Combination Therapies Targeting Apoptosis in Paediatric AML: Understanding the Molecular Mechanisms of AML Treatments Using Phosphoproteomics
por: Ali, Ahlam A., et al.
Publicado: (2023)

An Advanced Histologic Method for Evaluation of Intestinal Adenomas in Mice Using Digital Slides
por: Davis, Jennifer S., et al.
Publicado: (2016)

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis
por: Hurrish, Katie H., et al.
Publicado: (2023)

Multi-faceted role of LRP1 in the immune system
por: Sizova, Olga, et al.
Publicado: (2023)

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011)

A new inducible model for t(8;21) AML
por: Mulloy, James C
Publicado: (2013)

Impact of extramedullary disease in AML patients undergoing sequential RIC for HLA-matched transplantation: occurrence, risk factors, relapse patterns, and outcome
por: Fraccaroli, Alessia, et al.
Publicado: (2023)

Correlation of alteration of HLA-F expression and clinical characterization in 593 brain glioma samples
por: Feng, Enshan, et al.
Publicado: (2019)

Non-classical human leucocyte antigens in ankylosing spondylitis: possible association with HLA-E and HLA-F
por: Santos, Margarida Rodrigues, et al.
Publicado: (2018)

HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment
por: Wuerfel, Franziska M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bf3bll4fkgp85re74kbgbija2r